ArticleHealth science reports2025
Outcomes of Prostatic Artery Embolization for Treating Benign Prostatic Hyperplasia Symptoms: A Prospective Single-Center Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Review
- Minimally invasive vs standard surgical treatment: A systematic review comparing prostatic artery embolization and transurethral resection of the prostate for benign prostatic hyperplasia.Central European journal of urology · 2026Review
- Prostate Artery Embolization (PAE) in the Treatment of Benign Prostatic Hyperplasia: A Case Series and Narrative Review.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Benign prostatic hyperplasia (BPH) is among the most common urologic conditions in elderly men, presenting with lower urinary tract symptoms. Prostatic artery embolization (PAE) is a recent interventional treatment for BPH. Methods: This prospective single-center study reviewed the results of cases that underwent PAE for BPH from 2020 to 2022. Inclusion criteria were men with BPH refractory to pharmacologic treatment or those experiencing persistent adverse effects from medications, who were not candidates for surgical management. Assessments were made using ultrasonography for prostate volume and the International Prostate Symptom Score (IPSS) before and at 3 and 12 months after PAE. The clinical success rate of PAE was assessed according to the Cardiovascular and Interventional Radiological Society of Europe Standards of Practice. Recurrence of symptoms and complications after PAE were also recorded. Results: From a total of 46 included patients, clinical success was achieved in 93% at 3 months and 85% at 12 months. Complications occurred in eight (17.4%) cases, including five cases of erectile dysfunction and three cases of urinary tract infection. Eight (17.4%) cases had recurrent symptoms and required pharmacologic treatment, while seven (15.2%) needed surgery. The IPSS score dropped significantly at 3 months, with a mean difference of -16.2 (95% CI: -17.7 to -14.8) ( Conclusion: The findings of this study indicate that PAE is an effective therapeutic approach for patients with BPH, demonstrated by the low rates of adverse events and the absence of major complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.